Finshots Daily How can India’s pharma companies survive under Trump’s uncertainty?
6 snips
Jul 21, 2025 A recent $2 billion deal for a cancer drug signals a transformational shift for Indian pharma companies towards biopharmaceuticals. The podcast delves into the impacts of 'America First' policies on India's industry, emphasizing the urgent need for innovation. Moreover, it addresses the challenges posed by US drug pricing policies and the necessity for local companies to diversify into original research and development. The discussion also highlights the complexities of tariffs and patents, urging firms to enhance their competitiveness in an evolving market.
AI Snips
Chapters
Transcript
Episode notes
Glenmark's $2 Billion Cancer Drug Deal
- Glenmark signed a $2 billion licensing deal with AbbVie for an experimental cancer drug called ISB-2001.
- This drug is a first-in bispecific antibody designed to treat relapsed multiple myeloma, highlighting a new research-driven direction for Indian pharma.
US Price Cuts Threaten Indian Pharma Margins
- Indian pharma is heavily dependent on the US, with over 50% exports directed there.
- Trump’s push to slash drug prices by 30-80% threatens Indian generic drug margins, which are already razor-thin.
Manufacturing Abroad Isn't Enough
- Buying manufacturing plants abroad helps reduce tariffs and shipping costs but doesn't solve India's pharma value problem.
- The core challenge is to move up the value chain by investing in research and development for novel drugs.